vs
Side-by-side financial comparison of AerCap Holdings N.V. (AER) and Bausch Health Companies Inc. (BHC). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $1.9B, roughly 1.5× AerCap Holdings N.V.). AerCap Holdings N.V. runs the higher net margin — 66.7% vs -3.7%, a 70.4% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs -3.6%).
AerCap Holdings N.V. is an Irish-American aviation leasing company headquartered in Dublin, Ireland, with offices around the world. AerCap is listed on the NYSE with the ticker 'AER'. It became the largest aviation leasing company in the world following the acquisition of ILFC in 2014, and GECAS from GE in 2021, for over $30 billion.
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
AER vs BHC — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.9B | $2.8B |
| Net Profit | $1.3B | $-103.0M |
| Gross Margin | — | — |
| Operating Margin | 73.1% | 17.0% |
| Net Margin | 66.7% | -3.7% |
| Revenue YoY | -3.6% | 9.3% |
| Net Profit YoY | 181.0% | -205.1% |
| EPS (diluted) | $7.09 | $-0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $2.8B | ||
| Q3 25 | — | $2.7B | ||
| Q2 25 | $1.9B | $2.5B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | $2.0B | $2.4B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | — | $-103.0M | ||
| Q3 25 | — | $179.0M | ||
| Q2 25 | $1.3B | $148.0M | ||
| Q1 25 | — | $-58.0M | ||
| Q4 24 | — | $98.0M | ||
| Q3 24 | — | $-85.0M | ||
| Q2 24 | $448.2M | $10.0M | ||
| Q1 24 | — | $-64.0M |
| Q4 25 | — | 17.0% | ||
| Q3 25 | — | 23.1% | ||
| Q2 25 | 73.1% | 17.5% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | — | 21.8% | ||
| Q3 24 | — | 12.7% | ||
| Q2 24 | 25.1% | 16.2% | ||
| Q1 24 | — | 13.1% |
| Q4 25 | — | -3.7% | ||
| Q3 25 | — | 6.7% | ||
| Q2 25 | 66.7% | 5.8% | ||
| Q1 25 | — | -2.6% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | — | -3.4% | ||
| Q2 24 | 22.9% | 0.4% | ||
| Q1 24 | — | -3.0% |
| Q4 25 | — | $-0.30 | ||
| Q3 25 | — | $0.48 | ||
| Q2 25 | $7.09 | $0.40 | ||
| Q1 25 | — | $-0.16 | ||
| Q4 24 | — | $0.24 | ||
| Q3 24 | — | $-0.23 | ||
| Q2 24 | $2.28 | $0.03 | ||
| Q1 24 | — | $-0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.7B | $1.3B |
| Total DebtLower is stronger | $46.1B | $20.8B |
| Stockholders' EquityBook value | $17.9B | $-554.0M |
| Total Assets | $73.6B | $26.4B |
| Debt / EquityLower = less leverage | 2.57× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $2.7B | $1.7B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $719.0M | ||
| Q2 24 | $1.4B | $595.0M | ||
| Q1 24 | — | $733.0M |
| Q4 25 | — | $20.8B | ||
| Q3 25 | — | $21.0B | ||
| Q2 25 | $46.1B | $21.7B | ||
| Q1 25 | — | $21.5B | ||
| Q4 24 | — | $21.6B | ||
| Q3 24 | — | $21.5B | ||
| Q2 24 | $45.7B | $21.7B | ||
| Q1 24 | — | $22.1B |
| Q4 25 | — | $-554.0M | ||
| Q3 25 | — | $-565.0M | ||
| Q2 25 | $17.9B | $-764.0M | ||
| Q1 25 | — | $-1.2B | ||
| Q4 24 | — | $-1.3B | ||
| Q3 24 | — | $-1.2B | ||
| Q2 24 | $17.0B | $-1.2B | ||
| Q1 24 | — | $-1.1B |
| Q4 25 | — | $26.4B | ||
| Q3 25 | — | $26.8B | ||
| Q2 25 | $73.6B | $27.3B | ||
| Q1 25 | — | $26.4B | ||
| Q4 24 | — | $26.5B | ||
| Q3 24 | — | $26.5B | ||
| Q2 24 | $71.1B | $26.5B | ||
| Q1 24 | — | $26.9B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.57× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.69× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $495.0M |
| Free Cash FlowOCF − Capex | — | $403.0M |
| FCF MarginFCF / Revenue | — | 14.4% |
| Capex IntensityCapex / Revenue | — | 3.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $495.0M | ||
| Q3 25 | — | $405.0M | ||
| Q2 25 | — | $289.0M | ||
| Q1 25 | — | $211.0M | ||
| Q4 24 | — | $601.0M | ||
| Q3 24 | — | $405.0M | ||
| Q2 24 | — | $380.0M | ||
| Q1 24 | — | $211.0M |
| Q4 25 | — | $403.0M | ||
| Q3 25 | — | $314.0M | ||
| Q2 25 | — | $190.0M | ||
| Q1 25 | — | $96.0M | ||
| Q4 24 | — | $495.0M | ||
| Q3 24 | — | $334.0M | ||
| Q2 24 | — | $302.0M | ||
| Q1 24 | — | $129.0M |
| Q4 25 | — | 14.4% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | 4.2% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | — | 13.3% | ||
| Q2 24 | — | 12.6% | ||
| Q1 24 | — | 6.0% |
| Q4 25 | — | 3.3% | ||
| Q3 25 | — | 3.4% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 4.1% | ||
| Q3 24 | — | 2.8% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 3.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.26× | ||
| Q2 25 | — | 1.95× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.13× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 38.00× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AER
Segment breakdown not available.
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
